Kyverna Therapeutics, Inc.
KYTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001994702
No open-market purchases or sales by Kyverna Therapeutics, Inc. insiders were filed in the last 90 days; 120 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Kyverna Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Kyverna Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Seidenberg Beth C | Director | 21,727 | May 29, 2026 | 2 |
| Clark Ian T | Director | 21,727 | May 29, 2026 | 1 |
| Cohen Fred E | Director | 21,727 | May 29, 2026 | 1 |
| Shaw Christi | Executive Chairperson | 66,741 | May 29, 2026 | 2 |
| Aktar Mert | Director | 21,727 | May 29, 2026 | 1 |
| Martini Gregory S. | Chief Financial Officer | – | May 20, 2026 | 1 |
| Dac Nadia | Chief Commercial Officer | – | May 6, 2026 | 1 |
| Grasso Marc | Chief Financial Officer | 10,000 | Mar 17, 2026 | 1 |
| Biddle Warner Weston | Chief Executive Officer | 58,000 | Mar 17, 2026 | 1 |
| Gehchan Naji | See Remarks | 18,000 | Mar 17, 2026 | 1 |
| Miller Andrew Craig | Director | 11,006 | Mar 4, 2026 | 1 |
| Emany Sravan Kumar | Director | 11,006 | Feb 26, 2026 | 1 |
| Pujols Mayobanex | Chief Technology Officer | – | Feb 11, 2026 | 1 |
| Westlake BioPartners Fund I, L.P. | 10% Owner | 869,317Indirect | Dec 22, 2025 | 1 |
| Westlake BioPartners Opportunity GP I, LLC | 10% Owner | 869,317Indirect | Dec 22, 2025 | 1 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10% Owner | 869,317Indirect | Dec 22, 2025 | 1 |
| Westlake BioPartners GP I, LLC | 10% Owner | 869,317Indirect | Dec 22, 2025 | 1 |
| Walker Karen Marie | Chief Technology Officer | 22,636 | Dec 17, 2025 | 1 |
| Spiegelman Daniel K | Director | 16,634 | Jun 2, 2025 | 0 |
| Jones Ryan Alexander | Chief Financial Officer | 55,950 | Apr 15, 2025 | 0 |
| Vida Ventures, LLC | 10% Owner | 583Indirect | Feb 14, 2024 | 0 |
| Vida Ventures GP III, L.L.C. | 10% Owner | 583Indirect | Feb 14, 2024 | 0 |
| Vida Ventures III-A, L.P. | 10% Owner | 583Indirect | Feb 14, 2024 | 0 |
| Vida Ventures III, L.P. | 10% Owner | 583Indirect | Feb 14, 2024 | 0 |
| Harper Sean E | 10% Owner | 735,984Indirect | Feb 14, 2024 | 0 |
| Bain Capital Life Sciences Investors, LLC | 10% Owner | 3,163,868Indirect | Feb 14, 2024 | 0 |
| Bain Capital Life Sciences Fund III, L.P. | 10% Owner | 3,163,868Indirect | Feb 14, 2024 | 0 |
| Bain Capital Life Sciences Opportunities III, LP | 10% Owner | 3,163,868Indirect | Feb 14, 2024 | 0 |
| Bain Capital Life Sciences III General Partner, LLC | 10% Owner | 3,163,868Indirect | Feb 14, 2024 | 0 |
| Bain Capital Life Sciences Opportunities III GP, LLC | 10% Owner | 3,163,868Indirect | Feb 14, 2024 | 0 |
| Gilead Sciences, Inc. | 10% Owner | 4,126,119 | Feb 13, 2024 | 0 |
| Rubin Michael P. | Other: Former 10% Owner | 450,000Indirect | Feb 12, 2024 | 0 |
| Northpond Ventures III, LP | Other: Former 10% Owner | 450,000Indirect | Feb 12, 2024 | 0 |
| Northpond Ventures III GP, LLC | Other: Former 10% Owner | 450,000Indirect | Feb 12, 2024 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 22, 2025 (view filing)11:42 AM ET | Dec 18 | 4 days | Westlake BioPartners Fund I, L.P. and 3 others10% Owner | PPurchase | +133.3K | $7.50 | +$1.00M | +18.1%869.3K after | Duplicate filing |
| Dec 22, 2025 (view filing) | Dec 18 | 4 days | Seidenberg Beth CDirector | PPurchase | +133.3K | $7.50 | +$1.00M | +18.1%869.3K after | |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Walker Karen MarieChief Technology Officer | SSale | −24.0K | $12.20 | −$292.8K | −51.5%22.6K after | 10b5-1 |
| Feb 14, 2024 (view filing)7:04 PM ET | Feb 12 | 2 days | Vida Ventures, LLC and 3 others10% Owner | PPurchase | +253.1K | $22.00 | +$5.57M | New position583 after | 2 lots |
| Feb 14, 2024 (view filing)5:26 PM ET | Feb 12 | 2 days | Bain Capital Life Sciences Investors, LLC and 4 others10% Owner | PPurchase | +450.0K | $22.00 | +$9.90M | +16.6%3.16M after | |
| Feb 13, 2024 (view filing) | Feb 12 | 1 day | Gilead Sciences, Inc.10% Owner | PPurchase | +910.0K | $22.00 | +$20.0M | +28.3%4.13M after | |
| Feb 12, 2024 (view filing)5:51 PM ET | Feb 12 | Same day | Rubin Michael P. and 2 othersOther: Former 10% Owner | PPurchase | +450.0K | $22.00 | +$9.90M | New position450.0K after |